Aphaia Pharma AG

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

By 2040, over half a billion people could be taking GLP-1 agonists or other weight loss medicines, according to McKinsey. A market that barely existed prior to 2021 could be worth over $100bn by 2030

With GLP-1-based drugs ramping up staggering sales in obesity, and similar compounds in the clinic posting ever more impressive data, it is a brave company that chooses to pursue a non-incretin for th

Novo Nordisk ’s Wegovy and Eli Lilly ’s Zepbound have turned weight loss treatments into a multi-billion-dollar field but the sector is already looking to new approaches to see where cardiometabolic